AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03794050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training exercise
Description: randomized complete crossover for acute resistance training exercise session
Study NCT03794050 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training exercise
Description: randomized complete crossover for acute aerobic exercise training exercise session
Study NCT02939625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: muscle training
Study NCT02939625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Continue Positive Airway Pressure
Study NCT02939625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: bilevel positive airway pressure
Study NCT03151304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pracinostat
Description: 45 mg capsule
Study NCT03151304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: SC or IV injection
Study NCT00515918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: iron
Study NCT04411914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clavulanic Acid
Description: Drug will be given in 250mg capsules.
Study NCT04411914 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00426439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
Study NCT00426439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
Study NCT00426439 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (Coartem)
Description: Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
Study NCT00426439 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine (Coartem)
Description: Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, \< 34 kg: 4 tablets.
Study NCT04402840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate Ganglion Block
Description: The procedure will be done at the bedside in the ICU without interfering with ongoing treatment.
Study NCT04671121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standart pressure pneumoperitoneum
Description: CO2 insufflation pressure was kept at 14 mmHg throughout the surgery.
Study NCT04671121 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Low pressure pneumoperitoneum
Description: CO2 insufflation pressure was kept at 8 mmHg throughout the surgery.
Study NCT01256502 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: SERI® Surgical Scaffold
Description: Breast reconstruction surgery
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Day 2 \& 3: 3g/m2 IV over 2 hours q12 X 4
Study NCT00979199 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non invasive cardiac imaging
Description: Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
Study NCT00706485 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yttrium-90 Plaque Applicator
Description: Placed on the dura during surgery for 10-17 1/2 minutes
Study NCT04082338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VPN
Description: The intervention will be delivered through virtual patient navigation (VPN) toolkit system (a web/mobile application). The system includes education modules on HBV management, CHB patient success stories and virtual patient navigation clinical support for overcoming barriers.~In addition to the VPN, each participant will receive 5 text messages; one message once a week for 5 weeks on HBV management for every 6 months in the 18-month study period.
Study NCT04082338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TM
Description: Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
Study NCT04082338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TM
Description: Receive TM on HBV management respectively once a week for 5 weeks for every 6 months in the 18-month study period.
Study NCT01609023 — intervention group
Intervention type: DRUG
Intervention: Rituximab
Description: Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
Study NCT04220970 — intervention group
Intervention type: OTHER
Intervention: BIA-ALCL
Description: Observational : no intervention
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Day 1-4; 11-14: 40 mg daily
Study NCT02673814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Study NCT02673814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bavituximab
Study NCT00792961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endomicroscopy
Description: Rigid drop-in endomicroscope imaging probe
Study NCT02068703 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sleep Education Presentation
Description: Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
Study NCT02068703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Education Presentation
Description: Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
Study NCT02068703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Tool Demonstration
Description: Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
Study NCT00171951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pasireotide
Description: Pasireotide 600 μg or 900 μg was administered as an SC injection.
Study NCT00352417 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VIA-2291
Description: 100 mg, oral dosing, 1 time daily for 12 weeks
Study NCT00352417 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral dosing, 1 time daily for 12 weeks
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Hydrochlorothiazide 25 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril
Description: Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril
Description: Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisinopril and Hydrochlorothiazide
Description: L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisinopril and Hydrochlorothiazide
Description: L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifedipine XL
Description: 30 mg extended release tablets, 60 mg extended release tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nifedipine XL
Description: 30 mg extended release tablets, 60 mg extended release tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol tartrate
Description: 50 mg tablets \& 100 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Description: 50 mg tablets \& 100 mg tablets
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Day 4: 50 mg/m2 IV over 2 hours
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 600 mg/day
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: 50 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Description: 50 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: 80 mg tablets \& 160 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: 80 mg tablets \& 160 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxazosin
Description: 4 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: 4 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: 0.2 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clonidine
Description: 0.2 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: 50 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: 50 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metoprolol succinate
Description: 50 mg tablet \& 100 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate
Description: 50 mg tablet \& 100 mg tablet
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 5 mg tablets \& 10 mg tablets
Study NCT00661895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine
Description: 5 mg tablets \& 10 mg tablets
Study NCT02428946 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bromocriptine
Description: Investigating the randomized order for timing of bromocriptine administration
Study NCT03541018 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of repositional maneuvre
Description: Patients randomized to 2 different repositional maneuvres related to the subtypes of BPPV
Study NCT02165020 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (Macrolane VRF 30®, Q-MED)
Description: One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.~The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle.
Study NCT02357901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SUBOXONE
Description: SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
Study NCT02357901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SUBOXONE
Description: SUBOXONE (buprenorphine sublingual film) is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization. Following randomization, SUBOXONE use is tapered from 6 mg to 2 mg from Days 1-5 and then discontinued.
Study NCT02357901 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-6000
Description: Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either 300 mg or 100 mg dose.
Study NCT02357901 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen at volumes matching the experimental drug.
Study NCT01203046 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ertapenem
Description: Ertapenem 1 gr endovenous 3 or 7 days
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Day 1-3: 50mg IV BID
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegaspargase
Description: Day 3/Day4: 2,500 IU/ m2 IV
Study NCT01005914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Day 4 \& 11: 2 mg IV
Study NCT02707952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-493/ABT-530
Description: Co-formulated tablet
Study NCT01203046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ertapenem
Description: Ertapenem 1 gr endovenous 3 or 7 days
Study NCT01319812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Astron Stents
Description: Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
Study NCT01319812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsar Stents
Description: Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
Study NCT04371679 — intervention group
Intervention type: OTHER
Intervention: No interventions planned
Description: No interventions planned. Observational.
Study NCT03559153 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shiatsu massage
Description: The shiatsu massage will be during the rest break by 15 minutes.
Study NCT03559153 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Exercise
Description: The Physical Exercise will be during the rest break by 15 minutes.
Study NCT04463550 — intervention group
Intervention type: OTHER
Intervention: Description and analysis
Description: Retrospective, non-interventional study, using clinical, biological, radiological and therapeutic data collected during the initial diagnosis and follow-up.
Study NCT02707952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OBV/PTV/r
Description: Co-formulated tablet
Study NCT01633892 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fat Grafting
Study NCT00963287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bascial prescription plus or minus herbs depend on symptoms
Description: Decoction ,two times a day
Study NCT00963287 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bascial prescription plus or minus herbs depend on symptoms
Description: Decoction ,two times a day
Study NCT02116400 — intervention group
Intervention type: OTHER
Intervention: Interview
Description: All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
Study NCT02116400 — intervention group
Intervention type: OTHER
Intervention: Neuropsychological testing
Description: Neuropsychological tests are administered (requires computer use). See endpoints.
Study NCT02116400 — intervention group
Intervention type: BIOLOGICAL
Intervention: Serum concentration of lithium or sodium divalproate.
Description: Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
Study NCT02402309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active topical NS2 1% dermatologic cream
Study NCT02402309 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle placebo 0.0% NS2 dermatologic cream
Study NCT04853745 — intervention group
Intervention type: DEVICE
Intervention: AIR-FLOW® Master Piezon
Description: AIR-FLOW® Master Piezon is intended for use in the cleaning and polishing of teeth by the projection of water,air, and dental powders onto the tooth surface. The device removes dental plaque, soft deposits, and surface stains from pits, grooves, interproximal spaces, or smooth surfaces of teeth. This air polishing device was used for all powder instrumentations.
Study NCT02307357 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical fitness tests
Description: the subjects will perform 6 different tests to evaluate their physical fitness
Study NCT00687765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bsi-201 plus temozolomide
Description: BSI-201 given iv. 2x weekly, temozolomide given orally
Study NCT01701843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cromoglicate
Description: Twice daily topical treatment for 14 days
Study NCT01701843 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Twice daily topical treatment for 14 days
Study NCT04517565 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Brain magnetic resonance imaging
Description: Brain magnetic resonance imaging (MRI) will be done using multiple sequences to evaluate presence, type and severity of brain abnormalities in enrolled subjects.
Study NCT04517565 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuro-psychology testing
Description: Participants will undergo age-appropriate neuro-psychology testing to assess motor, language and other neuro-cognitive functions potentially affected by Sturge-Weber syndrome.
Study NCT04659850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: low fat, low AGE milkshake
Description: low fat, low AGE milkshake given after an overnight fast
Study NCT04659850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: low fat, high AGE milkshake
Description: low fat, high AGE milkshake given after an overnight fast
Study NCT04659850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high fat, low AGE
Description: high fat, low AGE milkshake given after an overnight fast
Study NCT04659850 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: high fat, high AGE milkshake
Description: high fat, high AGE milkshake given after an overnight fast
Study NCT02631850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional CI Therapy
Description: Intensive in-person therapy for upper extremity hemiparesis.
Study NCT02631850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming CI Therapy
Description: Intensive remote (via video game) therapy for upper extremity hemiparesis.
Study NCT02631850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Gaming CI Therapy with Additional Contact via Video Conference
Description: Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
Study NCT02631850 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Occupational Therapy/Physical Therapy
Description: Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
Study NCT01001507 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Integrated family planning/HIV care and treatment services
Description: Family planning services will be provided during the patient's HIV care visit.
Study NCT02347267 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric and non-caloric SSBS reduction
Description: Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
Study NCT02347267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Caloric SSBS reduction
Description: Isocaloric individualized diet and caloric SSBS restriction
Study NCT04473365 — intervention group
Intervention type: OTHER
Intervention: Intestinal parasite
Description: Pre-existing intestinal parasite infection present or absent at time of admission
Study NCT03417596 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Routine treatment
Study NCT03417596 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Routine treatment
Study NCT03417596 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vestibular Rehabilitation
Description: Exercise and rehabilitation programme was individualized
Study NCT02981524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Description: CY is administered intravenously at 200 mg/m2
Study NCT02981524 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GVAX
Description: GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
Study NCT02981524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab is administered intravenously at 200 mg